X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs CIPLA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA CIPLA ASTRAZENECA PHARMA/
CIPLA
 
P/E (TTM) x 61.1 24.5 249.0% View Chart
P/BV x 17.2 2.6 650.7% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ASTRAZENECA PHARMA   CIPLA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
CIPLA
Mar-18
ASTRAZENECA PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,278663 192.8%   
Low Rs883479 184.3%   
Sales per share (Unadj.) Rs228.4189.0 120.8%  
Earnings per share (Unadj.) Rs10.417.6 58.9%  
Cash flow per share (Unadj.) Rs16.334.0 47.8%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs98.8176.7 55.9%  
Shares outstanding (eoy) m25.00805.12 3.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.73.0 156.6%   
Avg P/E ratio x104.232.5 321.2%  
P/CF ratio (eoy) x66.416.8 395.9%  
Price / Book Value ratio x10.93.2 338.5%  
Dividend payout %017.1 0.0%   
Avg Mkt Cap Rs m27,008459,724 5.9%   
No. of employees `0001.423.6 5.7%   
Total wages/salary Rs m1,53526,901 5.7%   
Avg. sales/employee Rs Th4,210.96,446.1 65.3%   
Avg. wages/employee Rs Th1,132.21,139.4 99.4%   
Avg. net profit/employee Rs Th191.1600.0 31.8%   
INCOME DATA
Net Sales Rs m5,710152,193 3.8%  
Other income Rs m1233,577 3.4%   
Total revenues Rs m5,833155,769 3.7%   
Gross profit Rs m46328,264 1.6%  
Depreciation Rs m14713,228 1.1%   
Interest Rs m01,142 0.0%   
Profit before tax Rs m43817,470 2.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-28 0.0%   
Extraordinary Inc (Exp) Rs m0-775 0.0%   
Tax Rs m1792,501 7.2%   
Profit after tax Rs m25914,166 1.8%  
Gross profit margin %8.118.6 43.7%  
Effective tax rate %40.814.3 285.3%   
Net profit margin %4.59.3 48.8%  
BALANCE SHEET DATA
Current assets Rs m3,209108,141 3.0%   
Current liabilities Rs m2,07038,322 5.4%   
Net working cap to sales %20.045.9 43.5%  
Current ratio x1.62.8 55.0%  
Inventory Days Days7297 74.6%  
Debtors Days Days3574 46.9%  
Net fixed assets Rs m790109,411 0.7%   
Share capital Rs m501,610 3.1%   
"Free" reserves Rs m2,419140,682 1.7%   
Net worth Rs m2,469142,292 1.7%   
Long term debt Rs m036,621 0.0%   
Total assets Rs m4,605228,606 2.0%  
Interest coverage xNM16.3-  
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.20.7 186.2%   
Return on assets %5.66.7 84.0%  
Return on equity %10.510.0 105.4%  
Return on capital %17.710.0 178.2%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30051,691 0.6%   
Fx outflow Rs m2,01521,033 9.6%   
Net fx Rs m-1,71530,658 -5.6%   
CASH FLOW
From Operations Rs m8814,628 0.6%  
From Investments Rs m-94-8,540 1.1%  
From Financial Activity Rs mNA-3,855 0.0%  
Net Cashflow Rs m-62,431 -0.2%  

Share Holding

Indian Promoters % 0.0 16.0 -  
Foreign collaborators % 75.0 20.8 360.6%  
Indian inst/Mut Fund % 0.3 12.2 2.5%  
FIIs % 15.7 23.7 66.2%  
ADR/GDR % 0.0 1.1 -  
Free float % 9.1 26.2 34.7%  
Shareholders   12,856 161,166 8.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   GSK PHARMA  NATCO PHARMA  BIOCON   PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Witness Selling, Passenger Vehicles Sales Data, and Top Cues in Focus Today(Pre-Open)

India share markets witnessed selling pressure yesterday and ended their session deep in the red. At the closing bell yesterday, the BSE Sensex stood lower by 267 points (down 0.7%).

Related Views on News

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

More Views on News

Most Popular

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Super investor Pulak Prasad is Buying Stocks Big Time...and You Should Too(The 5 Minute Wrapup)

Aug 9, 2019

Here's why the relentless correction in the Indian stock markets has not unnerved the big investors.

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Aug 13, 2019

The dividends paid by these stocks are helpful when interest rates are falling.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

Qatar is Rearing Cows...this is Good News for India

Aug 9, 2019

Qatar has turned around after the Saudi embargo. This is good news for India.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 21, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS